Replimune Group (NASDAQ:REPL) Sets New 52-Week High – Here’s Why

Posted by Brian Himes on Nov 9th, 2026

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) reached a new 52-week high on Monday. The stock traded as high as $22.22 and last traded at $22.4440, with a volume of 248,937 shares. The stock had previously closed at $21.62.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target on the stock in a research report on Friday, August 7th. Leerink Partners lifted their price objective on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. JPMorgan Chase & Co. boosted their price objective on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.33.

Get Our Latest Stock Analysis on REPL

Replimune Group Stock Performance

The stock has a fifty day moving average of $14.09 and a 200-day moving average of $9.67. The firm has a market capitalization of $2.13 billion, a P/E ratio of -8.04 and a beta of 0.93. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59.

Replimune Group (NASDAQ:REPL – Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.24. On average, research analysts anticipate that Replimune Group, Inc. will post -2.40 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Emily Hill sold 9,256 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the transaction, the chief financial officer owned 215,852 shares of the company’s stock, valued at approximately $3,082,366.56. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kapil Dhingra sold 21,500 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $19.00, for a total transaction of $408,500.00. Following the completion of the transaction, the director directly owned 21,669 shares of the company’s stock, valued at approximately $411,711. This trade represents a 49.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.40% of the company’s stock.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Replimune Group during the 2nd quarter worth $99,171,000. Montanova Capital LLC boosted its position in shares of Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after acquiring an additional 168,000 shares during the period. Opaleye Management Inc. bought a new stake in shares of Replimune Group in the second quarter valued at about $15,332,000. Dimensional Fund Advisors LP boosted its position in shares of Replimune Group by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock valued at $8,719,000 after acquiring an additional 20,742 shares during the period. Finally, EcoR1 Capital LLC acquired a new position in shares of Replimune Group in the first quarter valued at about $7,650,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

(Get Free Report)

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.